Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) Receives Average Recommendation of “Moderate Buy” from Analysts

Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) has been assigned a consensus rating of “Moderate Buy” from the six analysts that are presently covering the stock, MarketBeat reports. One analyst has rated the stock with a sell recommendation, four have issued a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12-month price objective among brokerages that have updated their coverage on the stock in the last year is $19.00.

Several equities research analysts have recently weighed in on the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of Artiva Biotherapeutics in a research note on Tuesday, January 27th. Jefferies Financial Group raised shares of Artiva Biotherapeutics to a “strong-buy” rating in a research note on Tuesday, November 18th. Needham & Company LLC reiterated a “buy” rating and issued a $18.00 price target on shares of Artiva Biotherapeutics in a report on Friday, October 17th. HC Wainwright upped their price objective on Artiva Biotherapeutics from $12.00 to $15.00 and gave the company a “buy” rating in a research report on Wednesday, November 12th. Finally, Wedbush upped their price target on shares of Artiva Biotherapeutics from $18.00 to $23.00 and gave the stock an “outperform” rating in a report on Friday, October 17th.

Artiva Biotherapeutics Trading Down 2.9%

ARTV opened at $4.02 on Thursday. Artiva Biotherapeutics has a 12 month low of $1.47 and a 12 month high of $7.36. The stock has a 50-day moving average of $4.24 and a 200 day moving average of $3.57. The firm has a market cap of $98.69 million, a P/E ratio of -1.56 and a beta of 2.92.

Artiva Biotherapeutics (NASDAQ:ARTV) last announced its earnings results on Wednesday, November 12th. The company reported ($0.88) EPS for the quarter, topping analysts’ consensus estimates of ($0.92) by $0.04. On average, research analysts forecast that Artiva Biotherapeutics will post -4.95 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Artiva Biotherapeutics

A number of hedge funds have recently added to or reduced their stakes in ARTV. Prelude Capital Management LLC bought a new stake in shares of Artiva Biotherapeutics during the third quarter valued at approximately $41,000. Citadel Advisors LLC increased its holdings in Artiva Biotherapeutics by 419.3% during the 3rd quarter. Citadel Advisors LLC now owns 798,397 shares of the company’s stock worth $2,291,000 after purchasing an additional 644,658 shares during the period. Bank of America Corp DE raised its position in Artiva Biotherapeutics by 225.8% during the 3rd quarter. Bank of America Corp DE now owns 16,145 shares of the company’s stock valued at $46,000 after purchasing an additional 11,190 shares in the last quarter. Landscape Capital Management L.L.C. purchased a new stake in shares of Artiva Biotherapeutics in the 3rd quarter worth $112,000. Finally, BNP Paribas Financial Markets grew its position in shares of Artiva Biotherapeutics by 14,463.5% during the 3rd quarter. BNP Paribas Financial Markets now owns 118,547 shares of the company’s stock worth $340,000 after buying an additional 117,733 shares in the last quarter.

About Artiva Biotherapeutics

Artiva Biotherapeutics, Inc is a clinical-stage biotechnology company focused on the development of allogeneic “off-the-shelf” cell therapies for cancer. The company’s proprietary platform leverages natural killer (NK) cells engineered to express chimeric antigen receptors (CARs) or other targeting modalities, with the goal of delivering potent anti-tumor activity while minimizing the safety and supply limitations associated with patient-derived (autologous) approaches.

Artiva’s pipeline includes multiple lead product candidates designed to address both hematologic malignancies and solid tumors.